BI-PROFENID 150mg scored tab.

Država: Egipat

Jezik: engleski

Izvor: EDA (Egyptian Drug Authority)

Uputa o lijeku Uputa o lijeku (PIL)
06-05-2024

Dostupno od:

SANOFI AVENTIS-FRANCE

Doziranje:

150 mg

Farmaceutski oblik:

tablet

Jedinice u paketu:

20 tablets

Proizveden od:

SANOFI AVENTIS-EGYPT

Datum autorizacije:

2002-05-21

Uputa o lijeku

                                19/07/2018 12:04 - VISTAlink folder 3522968 - Page 1/2 1.NAME OF THE MEDICINE
BI-PROFENID 150 MG, SCORED TABLET
2.QUALITATIVE AND QUANTITATIVE COMPOSITION
White Layer( immediate release):
Ketoprofen............................................................
75, 00 mg
Yellow Layer(modified release ):
Ketoprofen............................................................
75.00 mg
For a scored tablet.
Excipient with a discernable effect: lactose
For a full list of excipients, see section 6.1.
3.PHARMACEUTICAL FORM
Scored tablet.
4.CLINICAL DATA
4.1 THERAPEUTIC INDICATIONS
They are derived from the analgesic and anti-inflammatory activity of
Bi-Profenid, The importance of the manifestations of intolerance to
which the
medicine gives rise, and its place in the range of anti-inflammatory
products
currently available.
They are limited, in adults and children from 15 years, to:
•Long-term symptomatic treatment:
oChronic inflammatory rheumatism conditions including rheumatoid
arthritis, ankylosing spondylitis (or related syndromes such as
Fiessinger-
Leroy-Reiter syndrome and psoriatic arthritis),
oOf certain painful and disabling arthroses.
•short-term symptomatic treatment of acute attacks:
oAbarticular rheumatism such as scapulo-humeral periarthritis,
tendonitis,
bursitis,
oMicrocrystalline arthritis,
oArthroses,
oLumbago,
oRadiculalgies,
oAcute benign post-traumatic affections of the musculoskeletal system.
•Treatment of the migraine crisis with or without aura.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
METHOD OF ADMINISTRATION: Orally.
The tablets should be swallowed as they are, with a large glass of
water.
DOSAGE
•Rheumatology:
oLong-term symptomatic treatment: 150 mg per day, either one
single-dose
tablet or two doses of half-tablets.
oShort-term symptomatic treatment of acute attacks: 300 mg per day, ie
two
tablets of 150 mg in 2 divided doses.
•Treatment of the migraine crisis:
It is recommended to take the treatment as early as possible, from the
beginning of the migraine crisis.
Begin the treatment 
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Uputa o lijeku Uputa o lijeku arapski 06-05-2024

Upozorenja za pretraživanje vezana za ovaj proizvod